Latest Biotech News

Amgen reported success for an injectable formulation of Tepezza (teprotumumab) in a Phase 3 study for thyroid eye disease, setting up an escalation in competition. The company’s move comes as...

Syneron Bio raised $150 million in a Series B round to develop a peptide drug class designed to borrow some of the properties of biologics. The company said the financing will support development...

Bristol Myers Squibb is partnering with Faro Health to use AI agents for clinical trial protocol design, drafting, validation and optimization. Faro’s technology structures narrative protocol...

Researchers from Sun Yat-Sen University reported a signaling–metabolic circuit that lets bladder tumors co-opt the local muscle microenvironment to generate metastatic blood-vessel niches. The...

Preclinical mouse data suggest cold plasma-activated water may inhibit breast cancer tumor growth. Researchers reported in a study on cold plasma-activated water’s effects against MCF7 breast...

A Nature Chemical Biology study reported a strategy to discover charged molecular glues enabled through targeted degron display. Molecular glues are small molecules that promote new...

A Phase 2 trial in acute myeloid leukemia reported encouraging results for a combination of quizartinib and omacetaxine mepesuccinate. The study, published in Nature Communications in 2026,...

A study in the British Journal of Cancer reported that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes for advanced ovarian cancer following neoadjuvant chemotherapy....

Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, adding Soleno’s Prader-Willi syndrome medicine Vykat to its portfolio and deepening its focus on rare diseases. The deal...

Takeda ended an eight-year partnership with Denali, returning full rights to Denali’s DNL593 ahead of the program’s Phase 1 steps. The termination arrives as Takeda continues restructuring, which...

Eli Lilly’s oral obesity drug Foundayo (orforglipron) won FDA approval, but the stock move quickly faded as investors weighed timing and competitive pricing versus Novo Nordisk’s oral Wegovy....

A four-month FDA delay forced Kezar Life Sciences to close its doors after the regulator canceled a key clinical-trial design meeting for an autoimmune hepatitis program. Kezar had reached an...

Researchers reported that circulating glycocholic acid (GCA) can influence the efficacy of immune checkpoint therapies in colorectal cancer, pointing to a potential biomarker and combination...

A phase II trial reported promising results for a combination of quizartinib and omacetaxine mepesuccinate in a high-risk AML setting. The study, published in Nature Communications in 2026,...

A study published in Nature Microbiology reported that the gut microbiome can modulate the efficacy and safety of Parkinson’s disease medications, highlighting drug–microbiome interactions as a...

Researchers reported that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes for patients with advanced ovarian cancer following neoadjuvant chemotherapy. The findings,...

Waseda University researchers unveiled a nanotube membrane-based injector designed to transfer cytoplasmic contents between living cell populations with high viability. Published in Small Science,...

Syneron Bio raised a $150 million Series B round to advance peptide programs built for improved drug-like properties, adding to its prior year fundraising efforts that totaled $100 million. The...

Eli Lilly’s oral obesity drug Foundayo (orforglipron) won FDA authorization, but the initial market reaction cooled quickly as investors weighed sales ramp and pricing pressure. Shares rose the...

Kezar Life Sciences shut down after an FDA delay derailed a planned clinical trial-design meeting for its autoimmune hepatitis program. The company said the FDA agreed on a trial plan but only...